Twenty-nine patients with acute myocardial infarction were treated with recombinant human tissue-type plasminogen activator (rt-PA). The incidence of acute coronary reocclusion and its prevention by a maintenance infusion of rt-PA were studied. Intravenous rt-PA was given at a rate of 0.4 to 0.75 mg/kg over 60 to 120 min after angiographic documentation of complete coronary occlusion. Reperfusion was accomplished within 1 hr in 24 of 29 patients (83%) and was associated with a decrease of the plasma fibrinogen level by 20%. In a first group of 13 patients, 1 1 of whom were successfully reperfused, prevention of reocclusion was attempted with heparin anticoagulation. However, acute reocclusion within 1 hr after cessation of rt-PA was demonstrated angiographically in five of these patients (45%). Quantitative angiographic analysis indicated that acute reocclusion only occurred in patients with 80% or greater residual stenosis. In patients with less than 80% residual stenosis, heparin anticoagulation was sufficient to maintain patency during the hospital stay in four of five patients. In a second group of patients (n = 16), 13 of whom underwent reperfusion with intravenous rt-PA, seven demonstrated a residual stenosis of 80% or greater. These patients were given heparin and, in addition, 10 mg of rt-PA per hour for 4 hr. None developed acute angiographic reocclusion or clinical signs of reocclusion during the hospital stay. Repeat angiography at 10 to 14 days confirmed persistent patency in six of the seven patients. The maintenance infusion resulted in only a moderate additional drop in fibrinogen, while a steady-state plasma rt-PA level of 750 250 ng/ml was maintained. In five of the six patients with less than 80% residual stenosis maintained on heparin therapy alone, follow-up angiography demonstrated persistent patency. These findings strongly suggest that a maintenance infusion of rt-PA may prevent or greatly reduce the reocclusion rate in patients with 80% or greater residual stenosis after coronary reperfusion with rt-PA.
THROMBOLYTIC THERAPY of acute myocardial infarction with streptokinase has often not produced stable coronary patency. The reported in-hospital reocclusion rate after reperfusion with intracoronary streptokinase has ranged from 5% to 29%, with an average of 17%. '61n our investigation of 34 patients with acute myocardial infarction, reocclusion after intracoronary streptokinase was seen in 18% within 2 hr, with an additional 9% of patients experiencing reocclusion before discharge.7 Angiographically documented reoc-clusion rates after intravenous streptokinase have been comparable.'-"
We and others"-'6 have recently studied the use of recombinant human tissue-type plasminogen activator (rt-PA), focusing n an intravenous dose that will produce rapid and safe reperfusion of occluded coronary arteries. These studies have revealed that rt-PA is an effective thrombolytic agent that produces coronary thrombolysis with less extensive systemic fibrinogenolysis than commonly observed with streptokinase. The problem of coronary reocclusion has thus far not been addressed in detail. We tested the hypothesis that thrombolysis with rt-PA might be complicated by a high rate of coronary rethrombosis and sought to determine whether reocclusion could be prevented or reduced by a maintenance infusion of rt-PA.
Methods
To receive the rt-PA infusion a total of 29 patients had to fulfill the following criteria: (1) acute "transmural" myocardial infarction with ST segment elevation of more than 0.1 mV in two standard electrocardiographic leads, (2) chest pain suggestive of infarction of less than 6 hr in duration, (3) age less than 70 years, (4) complete coronary occlusion documented angiographically before treatment, and (5) no contraindication to thrombolytic therapy. Written consent was obtained from each patient, and the study design was cleared by the hospital committee for human studies.
All patients were taken to the cardiac catheterization laboratory where they received a bolus of 5000 units of intravenous heparin followed by a continuous intravenous infusion of 1000 units/hr. The angiographic examination, which consisted of ventriculography in the 30 degree right anterior oblique position and selective angiography of both coronary vessels by the Judkins technique, was performed immediately.
After demonstration of complete coronary occlusion, each patient received intravenous rt-PA at a dose of 0.4 to 0.75 mg/kg over 60 to 120 min. Coronary angiography of the occluded vessel was performed at 15 to 30 mn intervals during the infusion with a primary angiographic end point at 90 min, which was used for quantitation of residual stenosis. During the initial phase of the study (n = 13), the patients were followed by repeat angiography at 15 min intervals for 1 hr after completion of the rt-PA infusion. After analysis of these patients revealed that high-grade residual stenosis (80% or greater of luminal diameter) was an important determinant of acute reocclusion, the study was continued in another 16 patients.
In these patients the same treatment regimen was applied, but the extent of residual stenosis was immediately estimated from the videographic recording taken at 90 min. Patients with an estimated residual stenosis of 80% or greater were immediately crossed over to a maintenance infusion of 10 mg of rt-PA per hour for 4 hr in addition to heparin infusion. The estimated degree of residual stenosis was subsequently verified by quantitative angiographic analysis.
All patients received intravenous nitroglycerin by continuous infusion for at least 24 hr at the time of reflow in a dose selected to reduce the arterial systolic blood pressure by 10%. Blood samples for determination of fibrinogen, plasminogen, a2-antiplasmin, and activated partial thromboplastin time (PTT) were obtained before treatment in all patients and 30 min after cessation of the therapeutic rt-PA infusion in all patients not receiving an rt-PA maintenance infusion. In patients receiving the maintenance dose of rt-PA, blood samples were taken at the start and 30 min after the end of the maintenance dose. In addition, blood samples for measurement of immunoreactive rt-PA were collected at specified intervals before, during, and after administration of rt-PA. Plasma fibrinogen levels were measured in plasma samples obtained from blood collected on O.O1M citrate (final concentration) and 200 KIU/ml aprotinin (Trasylol). Fibrinogen was assayed by a clotting rate assay (Clauss method)'7 or as total coagulable fibrinogen (Ratnoff and Menzie method)."8 a2-Antiplasmin, and t-PA-related antigen levels were measured on plasma samples collected on O.O1M citrate in the absence of aprotinin, as previously described.'9 Plasminogen was determined on citrated plasma with the chromogenic substrate S-2251 after conversion to plasminogen-streptokinase complex, following the instructions of the manufacturer (Kabivitrum, Stockholm, Sweden). Activated PTT was measured conventionally by the hospital clinical hematology laboratory.
Reperfusion was defined as complete distal opacification of the previously occluded coronary artery with washout of dye after injection in four cardiac cycles. Reocclusion was defined as complete interruption of antegrade flow at the previous site of obstruction. Acute reocclusion was treated in four patients with percutaneous transluminal coronary angioplasty (PTCA) and in one with intracoronary streptokinase followed by coronary artery bypass grafting (CABG).
All patients were transferred to the coronary care unit during continuous heparin infusion, which was adjusted to maintain the PTT at 11/2 to 2 times control for 10 to 14 days. The patients on rt-PA maintenance therapy were also transferred to the coronary care unit and received the same heparin infusion. After discontinuation of intravenous nitroglycerin, all patients were maintained on oral isosorbide dinitrate (60 to 160 mg/day) and diltiazem (120 to 240 mg/day). Repeat coronary angiography was performed at 10 to 14 days in 26 of 29 patients. Follow-up angiograms were not obtained in three patients: two of them underwent CABG for unstable angina and one patient refused to undergo repeat angiography.
Residual 
Results
The angiographically determined responses of the patients to the treatment schedules can be summarized as follows. In the first part of the study (heparin maintenance) 11 of 13 patients showed angiographic evidence of coronary reperfusion 90 min after the start of the therapeutic rt-PA infusion. Despite continued heparin anticoagulation, five of these patients experienced reocclusion, all within 1 hr after the end of the rt-PA infusion. Quantitation of residual coronary stenosis (figure 1, B) revealed that all of these patients had a residual stenosis of 80% or greater (87 + 2%, mean ± SD). The minimal luminal diameter was less than 0.44 mm (0. 37 ± 0. 1 mm), and the minimal cross-sectional area was less than 0.4 mm2 (0.11 + 0.04 mm2). After reocclusion, these five patients were treated either with acute PTCA (four) or with intracoronary streptokinase followed by CABG (one). The treated vessels in the six other patients with less severe residual stenosis (69 + 8%; figure 1 , A), a luminal diameter of 0.85 ± 0.2 mm, and a cross-sectional area of 0.68 ± 0.24 mm2, remained patent during the 1 hr observation period under heparin anticoagulation. During the follow-up period, one patient underwent CABG. Follow-up angiography performed in four patients revealed persistent patency. One patient refused follow-up angiography but showed no recurrence of ischemia inhospital.
In the second part of the study (rt-PA maintenance), 13 of 16 patients underwent reperfusion; six had a residual stenosis of less than 80% and seven a residual stenosis of 80% or greater as estimated from the videorecorder. Quantitative analysis of the cineangiogram indicated mean residual stenosis of 63 1 1%
(figure 1, C), luminal diameter of 1.0 ± 0.4 mm and cross-sectional area of 0.83 0.49 mm2 in the group with less severe stenosis; residual stenosis was 84 + 4% ( figure 1, D) , luminal diameter 0.55 0.16 mm, and cross-sectional area 0.26 ± 0.15 mm2 in the group with severe stenosis. All but one patient selected for rt-PA maintenance had a cross-sectional area less than 0.4 mm2. The seven patients with 80% or greater stenosis received a maintenance infusion of 10 mg/hr rt-PA for 4 hr in addition to heparin anticoagulation. None of these patients developed angiographic reocclusion within 1 hr. Angiography at 10 to 14 days showed persistent patency in six of the seven patients. During the hospital follow-up the residual stenosis in this group changed from 84 ± 4% to 70 + 20% (p < .1), the luminal diameter from 0.6 + 0.2 to 0.9 ± 0.6 mm, and the cross-sectional area from 0.26 + 0.15 to 0.96 + 1.0 mm2. Among the six patients with residual stenosis of less than 80% (63 11%) at the 90 min angiogram, one showed reocclusion on follow-up angiography ( figure 1, C) .
In total, 24 of 29 patients demonstrated complete reperfusion within 90 min after intravenous infusion of rt-PA. Analysis of the hemostasis data (table 1) indicated that there were no significant differences in the changes in the plasma levels of fibrinogen, plasminogen, or a2-antiplasmin between the patients with per-90min. 10 dys FIGURE 1. Percent residual diameter stenosis measured by quantitative angiographic analysis after reperfusion with rt-PA. Separation into subgroups was performed based on the degree of residual stenosis on the angiogram obtained 90 min after the beginning of the rt-PA infusion. Data on residual stenosis on follow-up angiography (at 10 days in A, C, and D; at 150 min in B) is included. (A, B, and C, Patients only treated with heparin following initial reperfusion. D, Patients with 80% or greater residual stenosis receiving additional treatment with a maintenance infusion of rt-PA. The open circles represent mean values and the vertical bars SD of the respective groups. sistent occlusion (n = 5), those with stable reperfusion under heparin anticoagulation during observation in the catheterization laboratory (n = 12), and those with acute reocclusion in the catheterization laboratory (n = 5). Plasma steady-state rt-PA levels, although individually quite variable, did not differ significantly between the groups. Fibrinogen levels measured by the method of Ratnoff and Menzie did not decrease below 78% of baseline, whereas values measured by a clotting rate method dropped to as low as 43% of the pretreatment value. The PTT was always maintained above 100 sec throughout the observation period. Plasminogen and a2-antiplasmin levels dropped to between 40% and 60% of the preinfusion values.
Results of analysis of hemostasis parameters at the The data represent mean + SD for values obtained in blood samples taken at the beginning and the end of the maintenance infusion. Plasma rt-PA levels are means of at least three determinations in each patient.
ADuring thrombolytic infusion; Bduring maintenance infusion.
beginning and after the rt-PA maintenance infusion are listed in table 2. The rt-PA maintenance infusion resulted in a steady-state plasma rt-PA level of 750 ± 250 ng/ml. This resulted in only moderate additional decreases in the plasma levels of fibrinogen of from 79% to 62% of the preinfusion value when measured as coagulable protein and from 68% to 52% when measured by the coagulation rate assay. Plasminogen and az2-antiplasmin levels only moderately decreased during the maintenance infusion.
The changes in plasma rt-PA levels during and after infusion in the five patients in whom acute reocclusion occured are shown in figure 2. Acute reocclusion occurred when the plasma rt-PA level decreased below approximately 700 ng/ml, which was within 60 min after cessation of therapy.
Discussion
Our results show that rt-PA is an effective thrombolytic agent in patients with acute myocardial infarction, producing coronary reflow in less than 1 hr in over 80% of the patients studied. These results are similar to the findings of the recently published multicenter studies. 11-6 However, the benefit of establishing coronary reperfusion is significantly offset by an acute spontaneous reocclusion rate of five of 11 patients notwithstanding full heparinization.
No differences were found between patients with stable reflow and acute reocclusion with respect to steady-state rt-PA levels, duration of infusion, localization of the coronary thrombus, time from onset of chest pain to reflow, or presence of residual filling defects. No differences were found in the extent to which the values of the activated PTT, fibrinogen, a2antiplasmin, or plasminogen levels changed during the 350 rt-PA infusion. Thus, patients stable after reperfusion as compared with patients with acute reocclusion had similar levels of heparin anticoagulation and fibrinolytic activation. In addition, reocclusion could not be attributed to a more rapid disappearance of circulating rt-PA after cessation of infusion.
Fibrinogen measured by the Clauss method, which is based on the rate of coagulation, decreased after infusion of rt-PA to approximately 60% of baseline. This decrease is essentially identical to that observed in the European rt-PA trial in which the same assay was used.'6 A less extensive drop in fibrinogen was measured with an alternative fibrinogen assay based on the method of Ratnoff and Menzie in which total coagulable protein is measured. This discrepancy confirms that some, but not complete, degradation of the fibrinogen molecule does occur during the infusion of rt-PA at the rates used in the present study.
Reocclusion was closely related to the degree of residual coronary stenosis (p < .001), whether or not it was produced by an angiographically visible filling defect. Acute reocclusion also only ocurred when circulating rt-PA levels had decreased to about 700 ng/ml. All patents were treated with intravenous nitroglycerin immediately after reflow was established, and patients suffering reocclusion received sublingual nifedipine without restoration of flow, indicating that coronary spasm was not a major contributing factor.
The features of rt-PA that make it a desirable agent are its clot specificity and short biological half-life, which allows fast restoration of an intact hemostatic system. Although, from a theoretical point of view, CIRCULATION rapid normalization of the coagulation system is desirable, this process might be associated with an increased frequency of acute coronary reocclusion. Our 45% initial acute reocclusion rate suggests that this may be a correct postulate. Although from our small series of patients it may seem that reocclusion after administration of rt-PA occurs both more frequently and earlier than after streptokinase infusion, the most important determinant for acute reocclusion appears to be the degree of residual stenosis. The close correlation between residual stenosis and reocclusion has been well documented by Harrison et al. and others'2 13 after coronary reperfusion with streptokinase. Coronary reocclusion may occur when residual cross-sectional area is less than 0.4 mm2 irrespective of the thrombolytic agent administered and even in the presence of extensive systemic fibrinogen breakdown.
Based on the hypothesis that acute reocclusion in patients with high-grade residual stenosis is coprecipitated by the potential presence of residual mural thrombus and of a thrombogenic injured vessesl wall, we attempted to prevent reocclusion by giving a maintenance rt-PA infusion in addition to the heparin anticoagulant treatment. This resulted in a remarkable reduction of the reocclusion rate both early after the initial reperfusion (vessels of all seven patients remaining patent) and at the end of the hospital stay (vessels of six of seven patients patent).
The reocclusion rate in the heparin maintenance group with 80% or greater residual stenosis was unusually high. The occurrence of this end point within 1 hr after cessation of infusion of rt-PA was not studied in the multicenter rt-PA trial.'5 In the present study it appears to relate to the rapid disappearance of rt-PA in the blood in the presence of only a mild reduction in circulating fibrinogen. Although this reocclusion rate in patients grouped by results of quantitative coronary angiography exceeds that reported by Harrison et al. ,12 the two studies are not strictly comparable. In our study acute reocclusion was treated with PTCA or CABG, precluding 10 day angiographic analysis. Therefore, spontaneous late recanalization could not be measured. Nevertheless, it is probable that the occurrence of reocclusion within 1 hr after administration of rt-PA in the presence of high-grade coronary stenosis exceeds that after longer acting fibrinolytic agents.
This study was designed to demonstrate the safety, hemostatic effects, and probably angiographic effects of a 4 hr maintenance infusion of rt-PA. We believe that a reduction in the acute reocclusion rate to zero is significant and that a late reocclusion rate of one of seven patients (14%) is encouraging.
Although our data were not obtained in a randomized study set-up, the observed differences were strikingly significant. The marked effect of a maintenance infusion of rt-PA on acute coronary reocclusion after initial reperfusion may have very significant consequences for the performance of coronary thrombolysis in patients with acute myocardial infarction. A maintenance infusion of rt-PA could delay or possibly eliminate the need for acute mechanical interventional procedures such as coronary angiography, PTCA, or CABG in some patients.
